Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: case report and review of literature

被引：6

作者：

de Andrade, Diocesio Pinto

Lima, Joao Paulo ^{[2
]}

Lima, Alan Duarte ^{[3
]}

Sasse, Andre Deeke ^{[2
]}

dos Santos, Lucas Vieira ^{[1
,2
]}

机构：

[1] Barretos Canc Hosp, Dept Med Oncol, GI Div, BR-14784400 Barretos, SP, Brazil

[2] Univ Estadual Campinas, Ctr Evidence Based Oncol, Fac Med Sci, Campinas, SP, Brazil

[3] Barretos Canc Hosp, Dept Radiol, BR-14784400 Barretos, SP, Brazil

来源：

ANTI-CANCER DRUGS | 2011年 / 22卷

关键词：

bevacizumab; case report; CEA; colorectal cancer; 5-fluorouracil; oxaliplatin; CETUXIMAB PLUS IRINOTECAN; PHASE-III TRIAL; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; CHEMOTHERAPY; COMBINATION; THERAPY; FLUOROPYRIMIDINE; SURVIVAL;

D O I：

10.1097/01.cad.0000398728.45590.11

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Bevacizumab-containing treatment is one of the approved first-line options for the management of metastatic colorectal cancer (CRC). Carcino-embryonic antigen (CEA) is a reasonable tumour marker for monitoring the efficacy of treatment. We report here a case of a 58-year-old male patient with metastatic CRC. He received first-line chemotherapy consisting of the mFOLFOX6 regimen plus bevacizumab. Initially he had an increase in CEA after which the level reduced, suggesting the occurrence of a CEA flare. The patient experienced a good response to therapy. In recent literature, CEA flare was identified as a good predictor of response to first-line chemotherapy. Anti-Cancer Drugs 22 (suppl 2):S15-S17 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

引用

页码：S15 / S18

页数：4

共 27 条

[1]

[Anonymous], ASCO GASTR CANC S

[2]

[Anonymous], J CLIN ONCOL SS15

[3]

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].